Progress in measurement instruments for acute and chronic gout studies

Journal of Rheumatology

Volumn 36, Issue 10, 2009, Pages 2346-2355

  Grainger, Rebecca ^a   Taylor, William J ^a   Dalbeth, Nicola ^b   Perez Ruiz, Fernando ^c   Singh, Jasvinder A ^d   Waltrip, Royce W ^e   Schlesinger, Naomi ^f   Evans, Robert ^g   Edwards, N Lawrence ^h   Sivera, Francisca ⁱ   Diaz Torne, Cesar ^j   Macdonald, Patricia A ^k   Mcqueen, Fiona M ^b   Schumacher, H Ralph ^d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c HOSPITAL DE CRUCES   (Spain)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Savient Pharmaceuticals   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g REGENERON PHARMACEUTICALS INC   (United States)

^h UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k TAP Pharmaceuticals   (United States)

more..

Author keywords

Gout; Instruments; Outcome measures

Indexed keywords

URIC ACID;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONSENSUS; CONSTRUCT VALIDITY; CONTENT VALIDITY; FACE VALIDITY; FEASIBILITY STUDY; GOUT; HUMAN; INTERNAL CONSISTENCY; JOINT SWELLING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; SHORT FORM 36; URIC ACID BLOOD LEVEL; WORK DISABILITY;

ACUTE DISEASE; ARTHRALGIA; CHRONIC DISEASE; CONSENSUS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DISABILITY EVALUATION; GOUT; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; URIC ACID;

EID: 70349253543     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090371     Document Type: Conference Paper

References (39)

1. Schumacher HR, Jr., Edwards LN, Perez-Ruiz F, et al. Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2452-2455. (Pubitemid 41780667)
2. Schumacher HR, Taylor W, Joseph-Ridge N, et al. Outcome evaluations in gout. J Rheumatol 2007;34:1381-1385.
3. Taylor WJ, Schumacher HR, Jr., Baraf HS, et al. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis 2008;67:888-891.
4. Schumacher HR, Taylor W, Edwards L, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:xxxx
5. Taylor WJ, Schumacher HR, Jr., Singh JA, Grainger R, Dalbeth N. Assessment of outcome in clinical trials of gout - a review of current measures. Rheumatol 2007;46:1751-1756. (Pubitemid 350168287)
6. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout-like arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-677.
7. Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatol 2007;46:1126-1132. (Pubitemid 47050616)
8. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-1860. (Pubitemid 351736009)
9. Schumacher HR, Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-1492.
10. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606. (Pubitemid 38202232)
11. Schlesinger N, Norquist JM, Holmes R, Boice J, Watson DJ. Validation of a patient-reported assessment of pain in acute gouty arthritis [abstract]. Ann Rheum Dis 2007;66:234.
12. Bolognese JA, Schnitzer TJ, Ehrich EW. Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. Osteoarthritis Cartilage 2003;11:499-507.
13. Norquist JM, Levine K, Schlesinger N, Boice JA, Watson DJ. Critical evaluation of recommended outcome assessments in acute gouty arthritis [abstract]. Ann Rheum Dis 2008;67:247.
14. Navarra S, Rubin BR, Yu Q, Smugar SS, Tershakovec AM. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout. Curr Med Res Opin 2007;23:1685-1691. (Pubitemid 47122178)
15. Grill E, Zochling J, Stucki G, et al. International Classification of Functioning, Disability and Health (ICF) Core Set for patients with acute arthritis. Clin Exp Rheumatol 2007;25:252-258.
16. Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999;131:756-759. (Pubitemid 29531985)
17. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-580.
18. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-325. (Pubitemid 38725128)
19. Becker MA, Schumacher HR, Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461. (Pubitemid 41781828)
20. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-360. (Pubitemid 34856121)
21. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007;34:1888-1893. (Pubitemid 350067651)
22. Taylor WJ, Shewchuk R, Saag K, Schumacher Jr HR, Singh JA, Grainger R, et al. Towards a valid definition of gout flare - results of consensus exercises using Delphi methodology and cognitive mapping. Arthritis Care Res 2009;61:535-543.
23. Schumacher HR, Jr, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005;32:2368-2372. (Pubitemid 41780649)
24. Wortmann RL, Becker MA, Schumacher HR, MacDonald PA, Hunt BJ, Joseph-Ridge N. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial [abstract]. Arthritis Rheum 2006;54:S642.
25. Dalbeth N, Clark B, Gregory K, Gamble GD, Doyle A, McQueen FM. Computed tomography measurement of tophus volume: comparison with physical measurement. Arthritis Rheum 2007;57:461-465. (Pubitemid 46682534)
26. Schumacher HR, Jr, Becker MA, Edwards NL, et al. Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract 2006;60:408-414.
27. Strand V. Design of and outcome measures for use in clinical trials in patients with osteoarthritis. In: Moskowitz RW, Buckwalter JA, Goldberg VM, Hochberg MC, editors. Osteoarthritis: diagnosis and medical/surgical management. Philadelphia: Lippincott Williams and Wilkens; 2006:313-325.
28. Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-1048.
29. Ruta DA, Hurst NP, Kind P, Hunter M, Stubbings A. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol 1998;37:425-436. (Pubitemid 28372200)
30. Alvarez-Hernandez E, Pelaez-Ballestas I, Vazquez-Mellado J, et al. Validation of the Health Assessment Questionnaire disability index in patients with gout. Arthritis Rheum 2008;59:665-669. (Pubitemid 351679541)
31. Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. Int J Clin Pract 2006;60:1210-1217.
32. Hirsch JD, Lee SJ, Terkeltaub R, Kanna D, Singh J, Sarkin A, et al. Evaluation of an instrument assessing influence of Gout on health-related quality of life. J Rheumatol 2008;35:2406-2414.
33. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health related quality of life and higher health care utilization in US veterans. Ann Rheum Dis 2008;67:1310-1316.
34. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology 2007;46:1441-1444. (Pubitemid 47317091)
35. Katz S, Down TD, Cash HR, Grotz RC. Progress in the development of the index of ADL. Gerontologist 1970;10:20-30.
36. Escorpizo R, Bombardier C, Boonen A, et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007;34:1372-1380. (Pubitemid 46898124)
37. Dalbeth N, Clark B, McQueen F, Doyle A, Taylor W. Validation of a radiographic damage index in chronic gout. Arthritis Rheum 2007;57:1067-1073. (Pubitemid 47237335)
38. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology 2007;46:1804-1807. (Pubitemid 350168295)
39. Becker MA, Schumacher HR, Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-923.